News

Article

E-602 Plus Cemiplimab Elicits Preliminary Antitumor Activity, Is Safe in PD-(L)1–Resistant Solid Tumors

Author(s):

Fact checked by:

Key Takeaways

  • E-602 and cemiplimab showed antitumor activity and tolerable safety in PD-(L)1-resistant solid tumors, including NSCLC and melanoma.
  • Tumor desialylation and decreased CD163-positive macrophages were observed post-treatment, indicating potential therapeutic benefits.
SHOW MORE

E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.

Lung Cancer

Lung Cancer

The combination of the first-in-class engineered human sialidase Fc fusion E-602 and cemiplimab-rwlc (Libtayo) elicited preliminary antitumor activity and displayed a tolerable safety profile in patients with anti–PD-(L)1–resistant solid tumors, including as non–small cell lung cancer (NSCLC) and melanoma, according to data from the phase 1/2 GLIMMER-01 trial (NCT05259696) shared at the 2024 SITC Annual Meeting.

Data showed that the E-602 combination produced tumor desialylation for 2 to 5 days following treatment despite rapidly clearing with a half-life of approximately 1 day. When excluding those with a baseline HYRDA histoscore of 20 or lower, tumor desialylation occurred in 9 of 10 patients.

CD163-positive tumor-related macrophages also decreased following therapy with E-602 plus cemiplimab. Excluding those with a baseline HYDRA histoscore of 20 or lower, 8 of 10 patients experienced decreases in tumor-related macrophages in tumors.

Among 15 patients with hypersialylation—those with a HYDRA histoscore of 20 or higher—partial responses (PRs) occurred in 7% (n = 1), stable disease occurred in 40% (n = 6), and progressive disease was reported in 53% (n = 8). The 1 patient who experienced a PR has remained on study treatment for more than 12 months at the time of analysis presentation. Among 5 of those who lacked hypersialylation and had HYDRA histoscores of lower than 20, all patients (100%; n = 5) had progressive disease following study therapy. The data indicate that desialylation of tumor cells exhibiting hypersialylation may be a potential therapeutic strategy among this patient population.

“Glycan editing of cell surface glycans offers a potential novel therapeutic approach to treat cancer. E-602, a first-in-class engineered human sialidase Fc fusion, has demonstrated safety, proof-of-mechanism, and early anti-tumor activity in combination with cemiplimab for patients with PD-1– and PD-L1–resistant solid tumors,” Manish R. Sharma, MD, co-director of Clinical Research at the START Center for Cancer Research – Midwest, stated in a presentation on these findings.

“A future goal of this program is to increase tumor desialylation duration to improve anti-tumor activity. There are 2 ways to potentially do that. One is to increase drug exposure by optimizing the human sialidase for an extended half-life. The other is to enhance tumor targeting by incorporating a tumor-targeting arm,” Sharma added.

According to Sharma, tumor cell sialoglycans can suppress innate and adaptive anti-tumor immunity, and desialylation of tumor cells may enhance these types of anti-tumor immunity.

In the monotherapy dose-escalation portion of the GLIMMER-01 trial, patients received E-602 at escalating doses of 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg. Investigators determined the recommended phase 2 dose as 20 mg/kg.

In part 2 of the GLIMMER-01 trial, patients received E-602 at 20 mg/kg once weekly plus cemiplimab at 350 mg every 3 weeks. The primary end points were safety and tolerability as well as objective response rate.

The cohort included 21 patients with PD-L1–resistant disease, with the most common tumor types including NSCLC (n = 12), melanoma (n = 8), and esophagogastric junction cancer (n = 1). The median age was 66 years (range, 42-82), and most patients were female (52%) and had an ECOG performance status of 1 at screening (67%). Most patients had baseline tumor hypersialylation (75%).

Combining E-602 with cemiplimab was shown to increase the level of peripheral cytokines compared with E-602 alone.

The treatment combination produced no dose-limiting toxicities, and investigators observed 1 treatment-related serious adverse effect (AE) consisting of a grade 3 infusion-related reaction. Grade 2 toxicity included infusion-related reactions (38%) and fatigue (10%). Additionally, grade 1 treatment-related AEs included nausea (10%), chills (10%), and fatigue (5%).

Reference

Sharma MR, Johnson M, Puzanov I, et al. GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors. Presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC); November 6-10, 2024; Houston, TX. Abstract 758.

Related Videos
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
John M. Burke, MD